

## **Mochida Pharmaceutical and Hospira Japan partner on distribution and co-promotion of oncology generic products in Japan**

-Collaboration represents an opportunity to expand access to generic products in the oncology area-

---

This material is an English translation of the press release issued on September 28, 2012 in Japanese, and the Japanese release is given priority regarding content and interpretation.

September 28, 2012

Mochida Pharmaceuticals Co., Ltd. today announced that Hospira Japan Co., Ltd. and Mochida have established a collaboration to distribute and co-promote Hospira generic oncology products in Japan.

As part of this agreement, both companies will co-promote “Irinotecan Hydrochloride I.V. drip infusion [Hospira]” and “Gemcitabine for I.V. infusion [Hospira]” commencing on October 1, and Mochida will be responsible for selling the products starting October 29. The collaboration between Hospira and Mochida also includes a range of new oncology generics to be launched in Japan in the future.

Hiroyuki Saeki, President and Representative Director, Hospira Japan, says, “One of Hospira’s key strategies is to “turbocharge growth” through global expansion and bringing more generic products to the world’s population. Japan, the world’s second largest healthcare market, is one of the most important countries for Hospira. We’re excited to collaborate with Mochida to expand access to our current and future oncology products with technology which is conscious of safe handling for healthcare professionals, and provides patients and healthcare providers with high-quality products in the oncology therapeutic area.”

Naoyuki Mochida, President of Mochida, says, “Mochida continues to research and develop the innovative products as a proprietary company and also engages in generic business. The partnership with Hospira, a company with a rich global experience in generic injectables, will accelerate our strategy to penetrate the generic oncology market for our expanding generic business. We expect our collaboration to meet the needs of patients and healthcare providers who require high-quality and value-added generic oncology products.”

The great combination of Hospira's global leadership in the generic injectable market with Mochida's brand as one of Japan's most trusted pharmaceutical companies creates a new position in the Japanese oncology market. The companies expect the strength of this partnership to greatly improve access to high-quality therapies for Japanese cancer patients.

Additional financial details of the agreement were not disclosed. This agreement will have only minor impact on the business performance of Mochida for the near term.